Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia

Cancer Chemother Pharmacol. 2002 Mar;49(3):251-5. doi: 10.1007/s00280-001-0402-6. Epub 2001 Dec 18.


Purpose: To evaluate the short-term adverse effects of administration of dolastatin-10 (Dol-10) to dogs with spontaneously occurring malignant tumors.

Methods: A total of 34 tumor-bearing dogs were given Dol-10 as a rapid intravenous bolus every 14 days at starting dosages ranging from 200 to 350 microg/m(2). Acute and short-term adverse effects, antitumor response, and duration of response were characterized.

Results: The maximum tolerated dose varied greatly from patient to patient, but a reasonable starting dose for further studies was established at 300 microg/m(2). The median number of treatments per dog was 2 (range 1 to 17). Granulocytopenia was the dose-limiting toxicity. The overall response rate was 3%, consisting of a complete and durable (30 months) response in a dog with high-grade malignant lymphoma that was refractory to standard therapy. Two minor or transient responses were observed, and two dogs experienced disease stabilization for 8 and 16 weeks.

Conclusions: Dol-10 appears to be well tolerated in tumor-bearing dogs at doses approaching those tolerated by humans. The clinical activity observed in dogs with non-Hodgkin's lymphoma warrants further investigation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Depsipeptides
  • Dog Diseases / drug therapy*
  • Dogs
  • Female
  • Male
  • Neoplasms / drug therapy
  • Neoplasms / veterinary*
  • Oligopeptides / adverse effects
  • Oligopeptides / therapeutic use*


  • Antineoplastic Agents
  • Depsipeptides
  • Oligopeptides
  • dolastatin 10